Oriana Kreutzfeld, Patrick K Tumwebaze, Martin Okitwi, Stephen Orena, Oswald Byaruhanga, Thomas Katairo, Melissa D Conrad, Stephanie A Rasmussen, Jennifer Legac, Ozkan Aydemir, David Giesbrecht, Barbara Forte, Peter Campbell, Alasdair Smith, Hiroki Kano, Samuel L Nsobya, Benjamin Blasco, Maelle Duffey, Jeffrey A Bailey, Roland A Cooper, Philip J Rosenthal
Malaria, especially Plasmodium falciparum infection, remains an enormous problem, and its treatment and control are seriously challenged by drug resistance. New antimalarial drugs are needed. To characterize the Medicines for Malaria Venture pipeline of antimalarials under development, we assessed the ex vivo drug susceptibilities to 19 compounds targeting or potentially impacted by mutations in P. falciparum ABC transporter I family member 1, acetyl-CoA synthetase, cytochrome b , dihydroorotate dehydrogenase, elongation factor 2, lysyl-tRNA synthetase, phenylalanyl-tRNA synthetase, plasmepsin X, prodrug activation and resistance esterase, and V-type H+ ATPase of 998 fresh P...
June 15, 2023: Microbiology Spectrum